Clinical Trial Update: An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead) [Phase 2, Phase 3]

View source ↗

Summary

Open-label, long-term safety study of REN001 in Primary Mitochondrial Myopathy was terminated; results were posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Myopathy

Drugs mentioned

• REN001

Snippet

Sponsor: Reneo Pharma Ltd | Conditions: Primary Mitochondrial Myopathy | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-05-28